Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,937
datasets available to search
ShareScore release 0.9.0
Dataset results
2,937 results for “Multiple Myeloma”
ArrayCGH microarray images for 'Autoencoder and NCA based neural network model to estimate survival prognosis in multiple myeloma using arrayCGH data'
<p>ArrayCGH microarray images for 'Autoencoder and NCA based neural network model to estimate survival prognosis in multiple myeloma using arrayCGH data'</p>
A single-cell atlas of multiple myeloma disease evolution
<p>A collection of computationally integrated (batch corrected) scRNA-seq and scTCR-seq data from a large cohort of bone marrow and peripheral blood samples from patients with multiple myeloma, myeloma precursor disease (MGUS and SMM) and non-cancer controls.</p> <h3>Datasets</h3> <ul> <li><strong>dataDescription.xlsx</strong> - Definition of dataset components.</li> <li><strong>panImmune.h5ad</strong> - All cells types integrated gene expression object.</li> <li><strong>Tcell.h5ad</strong> - T cells integrated object.</li> <li><strong>Tcell-scTCR.csv</strong> - Single-cell TCR data.</li> <li><strong>Botta_2023-predicted.h5ad</strong> - Single-cell gene expression data from Botta et al. analysed by label transfer.</li> <li><strong>metadata.donor.csv</strong> - Donor metadata.</li> </ul> <h3>Published data acquisition</h3> <p>Data shared through the gene expression omnibus (GEO) can be accessed for Maura et al. under accession GSE161195, Bailur et al. GSE163278, Oetjen et al. GSE120221, Granja et al. GSE139369, Zavidij et al. GSE124310, Kfoury et al. GSE143791, Botta et al. GSE205393, and Zheng et al. GSE156728. Data shared via dbGaP for Sklavenitis-Pistofidis et al. can be accessed under accession phs002476.v1.p1. Data shared online can be accessed for Stephenson et al. (via <a href="https://covid19cellatlas.org/">https://covid19cellatlas.org/</a>), Conde et al. (via <a href="https://www.tissueimmunecellatlas.org/">https://www.tissueimmunecellatlas.org/</a>), and Liu et al. (via <a href="https://explore.data.humancellatlas.org/projects/2ad191cd-bd7a-409b-9bd1-e72b5e4cce81">https://explore.data.humancellatlas.org/projects/2ad191cd-bd7a-409b-9bd1-e72b5e4cce81</a>). Single-cell data from <a href="https://doi.org/10.1016/j.ccell.2022.10.017" target="_blank" rel="noopener">Sklavenitis-Pistofidis et al.</a> and extended clinical data from <a href="https://doi.org/10.1038/s43018-023-00657-1">Maura et al.</a> (i.e. paraprotein) are omitted and must be acquired through direct contact with these authors.</p> <h3>Contact information </h3> <ul> <li>Kane Foster - kane.foster.web@gmail.com</li> <li>Kwee Yong - kwee.yong@ucl.ac.uk</li> </ul> <p>Please cite <a href="https://www.medrxiv.org/content/10.1101/2024.06.22.24309250v1">our pre-print</a> if you use this resource in your research.</p>
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression
<p> </p> <table> <tbody> <tr> <td>rowID</td> <td>filename</td> <td>date</td> <td>batch</td> <td>group</td> <td>ID</td> </tr> <tr> <td>1</td> <td>20200121_bm003696_RMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>RMM</td> <td>bm003696</td> </tr> <tr> <td>2</td> <td>20200121_bm054122_DRMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>DRMM</td> <td>bm054122</td> </tr> <tr> <td>3</td> <td>20200121_bm054496_RMM_tx_02.FCS</td> <td>20200121</td> <td>1</td> <td>RMM</td> <td>bm054496</td> </tr> <tr> <td>4</td> <td>20200121_bm059645_NDMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>NDMM</td> <td>bm059645</td> </tr> <tr> <td>5</td> <td>20200121_bm060791_NDMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>NDMM</td> <td>bm060791</td> </tr> <tr> <td>6</td> <td>20200121_bm064862_DRMM_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>DRMM</td> <td>bm064862</td> </tr> <tr> <td>7</td> <td>20200121_REF2_tx_01.FCS</td> <td>20200121</td> <td>1</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>8</td> <td>20200124_BM038232_RMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>RMM</td> <td>BM038232</td> </tr> <tr> <td>9</td> <td>20200124_BM051757_NDMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>NDMM</td> <td>BM051757</td> </tr> <tr> <td>10</td> <td>20200124_BM052673_DRMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>DRMM</td> <td>BM052673</td> </tr> <tr> <td>11</td> <td>20200124_BM053393_NDMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>NDMM</td> <td>BM053393</td> </tr> <tr> <td>12</td> <td>20200124_BM053570_RMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>RMM</td> <td>BM053570</td> </tr> <tr> <td>13</td> <td>20200124_BM059775_DRMM_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>DRMM</td> <td>BM059775</td> </tr> <tr> <td>14</td> <td>20200124_REF2_TAX_01.FCS</td> <td>20200124</td> <td>2</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>15</td> <td>20200128_3-1-BM060915-DRMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>DRMM</td> <td>BM060915</td> </tr> <tr> <td>16</td> <td>20200128_3-2-BM064896-DRMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>DRMM</td> <td>BM064896</td> </tr> <tr> <td>17</td> <td>20200128_3-3-BM059424-NDMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>NDMM</td> <td>BM059424</td> </tr> <tr> <td>18</td> <td>20200128_3-4-BM059429-NDMM_TX_02.FCS</td> <td>20200128</td> <td>3</td> <td>NDMM</td> <td>BM059429</td> </tr> <tr> <td>19</td> <td>20200128_3-5-BM043778-RMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>RMM</td> <td>BM043778</td> </tr> <tr> <td>20</td> <td>20200128_3-6-BM008007-RMM_TX_01.FCS</td> <td>20200128</td> <td>3</td> <td>RMM</td> <td>BM008007</td> </tr> <tr> <td>21</td> <td>20200129_3-7-ref2_tax_01.FCS</td> <td>20200129</td> <td>3</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>22</td> <td>20200204_5-1_BM054866-DRMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>DRMM</td> <td>BM054866</td> </tr> <tr> <td>23</td> <td>20200204_5-2_BM065069-DRMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>DRMM</td> <td>BM065069</td> </tr> <tr> <td>24</td> <td>20200204_5-3_BM035491-NDMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>NDMM</td> <td>BM035491</td> </tr> <tr> <td>25</td> <td>20200204_5-4_BM0333015-NDMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>NDMM</td> <td>BM0333015</td> </tr> <tr> <td>26</td> <td>20200204_5-5_BM0052990-RMM-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM0052990</td> </tr> <tr> <td>27</td> <td>20200204_5-5_BM0052990-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM0052990</td> </tr> <tr> <td>28</td> <td>20200204_5-5_BM052990-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM052990</td> </tr> <tr> <td>29</td> <td>20200204_5-6_BM052692-RMM-Tx_02.FCS</td> <td>20200204</td> <td>5</td> <td>RMM</td> <td>BM052692</td> </tr> <tr> <td>30</td> <td>20200204_5-7 -Ref2-Tx_01.FCS</td> <td>20200204</td> <td>5</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>31</td> <td>20200207_6-1_BM063515_DRMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>DRMM</td> <td>BM063515</td> </tr> <tr> <td>32</td> <td>20200207_6-2_BM054226_DRMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>DRMM</td> <td>BM054226</td> </tr> <tr> <td>33</td> <td>20200207_6-3_BM008346_NDMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>NDMM</td> <td>BM008346</td> </tr> <tr> <td>34</td> <td>20200207_6-4_BM008718_NDMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>NDMM</td> <td>BM008718</td> </tr> <tr> <td>35</td> <td>20200207_6-5_BM052764_RMM_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>RMM</td> <td>BM052764</td> </tr> <tr> <td>36</td> <td>20200207_6-6_Ref2_Tax_01.FCS</td> <td>20200207</td> <td>6</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>37</td> <td>20200211_7-1_BM061912_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM061912</td> </tr> <tr> <td>38</td> <td>20200211_7-2_BM059328_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM059328</td> </tr> <tr> <td>39</td> <td>20200211_7-3_BM065082_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM065082</td> </tr> <tr> <td>40</td> <td>20200211_7-4_BM008353_DRMM_TAX_01.FCS</td> <td>20200211</td> <td>7</td> <td>DRMM</td> <td>BM008353</td> </tr> <tr> <td>41</td> <td>20200211_Ref2_Tax_02.FCS</td> <td>20200211</td> <td>7</td> <td>REF</td> <td>REF2</td> </tr> <tr> <td>42</td> <td>20200214_4-1_BM062618_DRMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>DRMM</td> <td>BM062618</td> </tr> <tr> <td>43</td> <td>20200214_4-2_BM062255_DRMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>DRMM</td> <td>BM062255</td> </tr> <tr> <td>44</td> <td>20200214_4-3_BM032596_NDMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>NDMM</td> <td>BM032596</td> </tr> <tr> <td>45</td> <td>20200214_4-4_BM047845_NDMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>NDMM</td> <td>BM047845</td> </tr> <tr> <td>46</td> <td>20200214_4-5_BM042666_RMM_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>RMM</td> <td>BM042666</td> </tr> <tr> <td>47</td> <td>20200214_4-6_Ref2_Tax_01.FCS</td> <td>20200214</td> <td>4</td> <td>REF</td> <td>REF2</td> </tr> </tbody> </table> <p> </p> <p>*files with row ID #26 and #27 need to be concatenated since they represent the same sample acquired over 2 files</p>
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
ClinicalTrials.gov study NCT02312258. IPD Sharing: YES. Countries: 35. Publications: 2.
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02290431. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03215030. IPD Sharing: YES. Countries: 16. Publications: 2.
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
ClinicalTrials.gov study NCT02990338. IPD Sharing: YES. Countries: 24. Publications: 8.
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov study NCT03439293. IPD Sharing: YES. Countries: 6. Publications: 0.
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02917941. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Inject
ClinicalTrials.gov study NCT03416374. IPD Sharing: YES. Countries: 1. Publications: 1.
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
ClinicalTrials.gov study NCT02761187. IPD Sharing: YES. Countries: 15. Publications: 5.
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
ClinicalTrials.gov study NCT02812706. IPD Sharing: YES. Countries: 1. Publications: 2.
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov study NCT01850524. IPD Sharing: YES. Countries: 7. Publications: 1.
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
ClinicalTrials.gov study NCT03275285. IPD Sharing: YES. Countries: 16. Publications: 10.
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
ClinicalTrials.gov study NCT02181413. IPD Sharing: YES. Countries: 33. Publications: 4.
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
ClinicalTrials.gov study NCT03433001. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
ClinicalTrials.gov study NCT04776018. IPD Sharing: YES. Countries: 2. Publications: 1.
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
ClinicalTrials.gov study NCT03170882. IPD Sharing: YES. Countries: 18. Publications: 1.
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
<p>BCMA-targeted CAR-T therapy has shown potent treatment outcomes in treating multiple myeloma (MM), a disease characterized by malignant bone marrow (BM) plasma cells. However, the remodeling of MM microenvironment after CAR-T therapy remains poorly understood. Here, we report the reconstitution of MM microenvironment by obtaining single-cell transcriptomes for paired BM specimens (n = 14) from 7 MM patients before (<em>i.e.</em>, baseline, ''day −4'') and after (<em>i.e.</em>, ''day 28'') post-lymphodepleted BCMA CAR-T therapy. Our analysis revealed heterogeneity in driver gene expression among MM cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8<sup>+</sup> effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells (Tregs), enhanced CD8<sup>+</sup> effector T cell cytotoxic activity, and elevated type 1 conventional dendritic cell (cDC1) antigen presentation ability. DC re-clustering inferred intramedullary-originated cDC3s with extramedullary migration. Cell-cell communication network analysis indicated BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway-mediated immunosuppression and activates MIF pathway-mediated anti-MM immunity. Our study sheds light on MM microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.</p>
1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT02289222. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.